Is ZLAB's Q1 2025 EPS forecast achievable?

**Zai Lab's Q1 2025 EPS forecast is achievable**, based on the following points:

1. **Consistent Growth Trajectory**: Zai Lab has demonstrated a strong growth trajectory in its net product revenue, which increased by 49% year-over-year to $397.6 million in 2024. This growth momentum suggests that the company is on track to achieve its revenue targets, including the $2 billion target by 2028.
2. **Financial Performance and Guidance**: Zai Lab's financial performance in 2024, with net product revenue growth and a reduction in R&D expenses and net losses, indicates a strong financial health. The company's guidance for FY 2025 revenue of $560 million to $590 million aligns with the EPS increase trajectory.
3. **Insider Confidence**: Recent insider transactions, such as the sale of shares by executives, can be indicative of confidence in the company's future performance. The fact that these transactions were made to cover taxes upon vesting of Restricted Share Units (RSUs) suggests that the executives believe the stock price will remain high enough to cover the tax liability, which implies a positive outlook on the company's future performance.
4. **Analyst Optimism**: Analysts have maintained an "Overweight" rating on Zai Lab, emphasizing the potential of Bemarituzumab as a growth driver. The drug is undergoing Phase 3 trials, and positive outcomes could significantly impact Zai Lab’s future growth. Additionally, Scotiabank's Sector Outperform rating and projected cash flow positivity by the fourth quarter of 2025 suggest a positive outlook for the company's financial performance.

In conclusion, Zai Lab's Q1 2025 EPS forecast is achievable based on the company's historical growth, financial performance, insider transactions, and analyst optimism.